Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. It focuses on the treatment of a spectrum of diseases, as well as utilizing bioengineering in drug design. Its product pipeline includes SBI-100 and SBI-200. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.